For research use only. Not for therapeutic Use.
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis[1].
Briakinumab targets the p40 molecule shared by interleukin-12 and interleukin-23[2].
| Catalog Number | I042151 |
| CAS Number | 339308-60-0 |
| Purity | ≥95% |
| Reference | [1]. Panaccione R, et, al. Briakinumab for treatment of Crohn’s disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun;21(6):1329-40. [2]. Reich K, et, al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011 Oct 27;365(17):1586-96. |
